Korea Republic Of

Genexine, Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Genexine Consortium Develops COVID-19 Vaccine for Human Testing

Lead Product(s): GX-19

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2020

Details:

GX-19 is a potential COVID-19 vaccine developed based on Genexine’s DNA vaccine know-how. The consortium will apply for clinical testing of GX-19 within May, and is expecting to begin testing the vaccine on patients starting early June.

DongWha Pharm

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

DongWha Pharm to Kick Off Trials for Virus Treatment

Lead Product(s): DW2008

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 06, 2020

Details:

In vitro antiviral experiments performed against COVID-19 demonstrated that DW2008 had 1.7, 3.8, and 4.7 times higher antiviral activity compared to chloroquine, remdesivir, and Kaletra respectively.

Samsung Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Samsung Inks $362M Deal To Boost Vir's COVID-19 Antibody Output

Lead Product(s): VIR-7831

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Vir Biotechnology

Deal Size: $362.0 million Upfront Cash: Undisclosed

Deal Type: Agreement April 09, 2020

Details:

Through this deal parties are trying to scale up manufacturing of Vir's monoclonal antibody program as a potential treatment for COVID-19.

GemVax & KAEL

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Gemvax & Kael Expands GV1001 Patent To Cover COVID-19

Lead Product(s): Tertomotide

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 31, 2020

Details:

GV1001 has been proven to relieve the aforementioned conditions, as well as help boost immune system, in the preclinical trial phase.

Cellivery

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Cellivery, Icp-NI 'Corona 19' Primate Treatment Efficacy Verification Begins

Lead Product(s): iCP-NI

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 27, 2020

Details:

The new drug iCP-NI begins to verify the efficacy of treatment for the treatment of acute pneumonia and severe sepsis caused by corona19.

Novacell

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Novacell, AD Korea Corona 19 treatment joint development MOU

Lead Product(s): Heptameric peptide FPR2

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: AD Korea

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 06, 2020

Details:

The two companies will promote joint research and development to develop new drugs for the treatment of severe diseases of viral respiratory diseases, such as corona19, using the candidate NCP112.

G+FLAS Life Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

G+FLAS Life Sciences Readying Animal Testing Of Coronavirus Vaccine Candidate

Lead Product(s): Immunogenic recombinant vaccine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 06, 2020

Details:

G+FLAS has constructed an immunogenic recombinant vaccine candidate expressed in transgenic plants based on its own plant-based protein production platform.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

Genexine, Inc

Genexine Consortium Develops COVID-19 Vaccine for Human Testing

DongWha Pharm

DongWha Pharm to Kick Off Trials for Virus Treatment

Samsung Biologics

Samsung Inks $362M Deal To Boost Vir's COVID-19 Antibody Output

GemVax & KAEL

Gemvax & Kael Expands GV1001 Patent To Cover COVID-19

Cellivery

Cellivery, Icp-NI 'Corona 19' Primate Treatment Efficacy Verification Begins

Novacell

Novacell, AD Korea Corona 19 treatment joint development MOU

G+FLAS Life Sciences

G+FLAS Life Sciences Readying Animal Testing Of Coronavirus Vaccine Candidate